23. Pharmacology and Neuroscience of Antipsychotic Drugs

  1. Daniel R. Weinberger MD3 and
  2. Paul J. Harrison MA, BM, BCh, DM(Oxon), FRCPsych4
  1. John L. Waddington PhD, DSc1,
  2. Colm M. P. O'Tuathaigh PhD1 and
  3. Gary J. Remington MD, PhD, FRCPC2

Published Online: 8 MAR 2011

DOI: 10.1002/9781444327298.ch23

Schizophrenia, Third Edition

Schizophrenia, Third Edition

How to Cite

Waddington, J. L., O'Tuathaigh, C. M. P. and Remington, G. J. (2010) Pharmacology and Neuroscience of Antipsychotic Drugs, in Schizophrenia, Third Edition (eds D. R. Weinberger and P. J. Harrison), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327298.ch23

Editor Information

  1. 3

    Genes, Cognition and Psychosis Program, Clinical Studies Section, Clinical Brain Disorders Branch, National Institute of Health, Bethesda, MD, USA

  2. 4

    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK

Author Information

  1. 1

    Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

  2. 2

    Centre for Addiction and Mental Health, Faculty of Medicine, University of Toronto, Toronto, Canada

Publication History

  1. Published Online: 8 MAR 2011
  2. Published Print: 10 DEC 2010

ISBN Information

Print ISBN: 9781405176972

Online ISBN: 9781444327298



  • antipsychotics;
  • therapeutic efficacy;
  • adverse effects;
  • dopamine;
  • serotonin;
  • glutamate;
  • PET;
  • SPECT;
  • psychological mechanisms


This chapter seeks to document advances and controversies in relation to mechanisms underlying the therapeutic and adverse effects of antipsychotic drugs. It focuses on findings for second-generation agents, with an emphasis on neuroimaging studies in living patients; yet it is mindful of what we have learned and have still to learn from their first-generation counterparts. Thereafter, it considers putative “third-generation” agents, and then considers novel mechanisms and possible future developments.